US Biotech, HiberCell, Acquires Genuity Science. Read more here.

The Genomic Basis of
Chronic Obstructive Pulmonary Disease (COPD)

We do not know exactly what causes Chronic Obstructive Pulmonary Disease (COPD), but scientists believe that genetic make-up combined with environmental and lifestyle factors may be at play. The Genuity Science COPD research study aims to explore this relationship between genomics, COPD, and environmental/lifestyle factors to identify patterns that will help deepen our understanding of the disease.

Genuity Science is working to bridge the knowledge gap

COPD affects up to 174 million people worldwide and approximately 3 million people die each year from COPD or COPD-related complications. Despite this high prevalence, COPD is an underdiagnosed condition and remains poorly understood. This is partially due to its extremely heterogeneous and complex nature, specifically in terms of its clinical outcomes, disease severity, and progression1. This genomics study will develop a comprehensive research resource on COPD that may have the ability to identify differences and similarities between disease mechanism in participants with COPD, improving how we stratify patients for treatments and clinical trials based on a patient’s genetic profile. Enhancing our knowledge will accelerate the development of novel therapeutics and strategies, ultimately resulting in better treatments available to patients.

Aims of the Genuity Science COPD Study

  • to understand why some people develop COPD and others do not
  • to determine why some people develop a mild form of COPD while others develop a more severe form
  • to identify lifestyle or environmental triggers of COPD
  • to identify genetic markers that will help with the early diagnosis of COPD
  • to identify people at risk of more severe forms, and through our partnerships, identify new or more effective treatments for COPD. 

Genomics Medicine for Precision Health

A genetic biomarker is described as a known DNA sequence that causes disease or is associated with susceptibility to disease. Using genetic biomarkers to predict the severity of MS for a person as well as how that person is likely to respond to treatment would tremendously improve our ability to manage the disease for that patient. Precision health is about prescribing an individual patient with the right drug, at the the right dose, at the right time. This would allow for earlier intervention and the increased potential to slow progression.

COPD and Classification

COPD is the collective term for a complex group of lung diseases that includes chronic bronchitis, emphysema, and chronic obstructive airways disease. These chronic diseases are characterised by a gradual progressive decline in lung function with partially reversible airflow obstruction, systemic manifestations and increasing frequency and severity of exacerbations over time.

Genuity Science's COPD Research Study

The Genuity Science COPD study is a population-based study, which means the data is grouped with thousands of other participants with COPD so that researchers can identify patterns that may help answer some important questions about the disease. This exploration of genetic and environmental risk factors, as well as the biological processes associated with COPD, will contribute to a better overall understanding of COPD, paving the way for the development of new treatments and earlier intervention therapies for COPD patients.

Sign up for our newsletter

News, information, and education. You can unsubscribe at anytime.

Related Videos

What is Genomics?

This short video shines some light on this big question.

Genuity Research Participation Overview

Discover the steps involved in the research participation process.

The Journey of a Blood Sample

Follow what happens to a blood sample once it is collected.

Genuity Science Data Privacy

Learn more about how seriously we take your data privacy.